SelectHealth will cover PGx testing for Intermountain employees and beneficiaries with major depressive disorder who have failed treatment.
In Nature this week: residual protein expression uncovered for a third of CRISPR targets, and more.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
Researchers also uncovered associations between any psychotic experience and the genetic liability for schizophrenia, major depressive disorder, and bipolar disorder.
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.
With $200M in new investment, the precision medicine firm has launched a clinical trial matching service, is adding clinical data to TCGA, and is moving into the Asian market.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.